Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Addressing ESG issues may help pharma to repair its reputation

As pharmaceutical companies continue to grapple with issues ranging from lack of transparency on pricing, price gouging to questionable ethical practices and clinical data reporting processes, addressing environmental, social, and governance (ESG) issues will continue to be an important, and perhaps beneficial theme for the industry in 2021, says GlobalData a leading data and analytics company. In a recent GlobalData poll* it was highlighted that environmental issues were viewed as the most important ESG area […]
Read more

Bio/Pharma companies’ Q4 2020 market performance impacted by development of treatments or vaccines for COVID-19

The market performance of the top 20 Bio/Pharma companies is still being impacted by the COVID-19 pandemic, either positively for companies developing a vaccine for the disease or negatively for those working on a treatment, says GlobalData, a leading data and analytics company. Madeleine Roche, MSc, Analyst at GlobalData comments: “Drug sales for Q4 2020 heavily influenced company performance, with COVID-19 vaccines driving market cap growth, but COVID-19 therapeutics possibly causing a decline. The top 10 companies (Johnson & Johnson, F. Hoffmann-La Roche, Novartis, Merck & Co, Pfizer, AbbVie, Eli […]
Read more

Diagnosed prevalent cases of HIV to reach 2.1 million by 2029 in the 7MM

The diagnosed prevalent cases of human immunodeficiency virus (HIV) in the seven major markets (7MM*) are projected to increase from 1.87 million in 2019 to 2.1 million in 2029, with an annual growth rate (AGR) of 1.06%, according to GlobalData, a leading data and analytics company. The company’s latest report, ‘Human Immunodeficiency Virus (HIV): Epidemiology […]
Read more

VELREAL study results may bolster current use of Velphoro among CKD-Hyperphosphatemia patients on dialysis

Velphoro’s (sucroferric oxyhydroxide) recent VELREAL multicenter study showed a 20% decrease in serum phosphorus in addition to reduced parathyroid hormone level in chronic kidney disease (CKD) patients on dialysis. This study could be of high clinical value to physicians with dialysis patients looking to find an optimal treatment of choice for hyperphosphatemia (HP) and hyperparathyroidism, […]
Read more

SARS-CoV-2 mutations could make COVID-19 endemic

The recent SARS-CoV-2 virus variant in South Africa (B.1.351) underscores a critical weakness in combatting the COVID-19 epidemic and may prolong it indefinitely, says GlobalData, a leading data and analytics company. South Africa made headlines when it announced that it would be suspending AstraZeneca’s COVID-19 vaccine (AZD1222). The vaccine’s efficacy was below 25% in South […]
Read more

Success in Parkinson’s disease development pipeline relies on Roche’s prasinezumab overcoming recent string of failures

The Parkinson’s disease (PD) pipeline has been hit significantly with a string of failures among its most anticipated mid-stage pipeline candidates. This news presents a challenge for similar disease-modifying therapies (DMTs) undergoing development such as Roche’s prasinezumab. It also amplifies that a major unmet need remains in bringing DMTs and neuroprotective agents to this market, […]
Read more

Sales of injectable anti-HIV therapeutics will reach US$2bn in 2029

The human immunodeficiency virus (HIV) therapeutics market was worth an estimated $22.9bn across the seven major markets (7MM*) in 2019. The market is expected to grow at a Compound Annual Growth Rate (CAGR) of 2%, reaching $28bn in 2029, according to GlobalData, a leading data and analytics company. GlobalData’s latest report, ‘HIV Therapeutics: Global Drug Forecast and Market Analysis to 2029’, reveals that growth in the market will be driven by […]
Read more

EOC Pharma well-positioned to bring innovative oncology drugs to China, says GlobalData

China-based EOC Pharma has recently entered an in-licensing partnership with US-based biopharmaceutical company Aadi Bioscience for the development and commercialization of ABI-009 (Fyarro). This deal, along with the previous in-licensing deals, clearly highlights EOC Pharma’s strategy to bring innovative oncology therapies for Chinese patients, says GlobalData, a leading data and analytics company. Under the agreement, […]
Read more

Gilead and Galapagos discontinuing IPF Phase III front-runner is a major setback in the disease space

Gilead and Galapagos recently announced the discontinuation of the ISABELA Phase III clinical trials investigating ziritaxestat, a once daily autotaxin inhibitor formerly known as GLPG-1690, in patients with idiopathic pulmonary fibrosis (IPF). Due to IPF’s high clinical unmet needs, this discontinuation represents a major setback in the disease space, according to GlobalData, a leading data […]
Read more

Takeda continues collaboration run to bolster global immuno-oncology footprint, says GlobalData

The need to develop novel innovative cancer drugs at affordable prices is forcing large pharmaceutical firms to collaborate with biotech companies and academic institutions. Japan-based Takeda Pharmaceuticals too is focusing on strategic collaborations to bolster its global immuno-oncology (IO) footprint, says GlobalData, a leading data and analytics company. In January 2021, Takeda entered a broad […]
Read more

Caladrius Biosciences’ US sales of CLBS16 in CMD to reach $346m by 2028, despite market entry hurdles

Caladrius Biosciences’ initiation of the Phase IIb FREEDOM trial of its autologous CD34+ stem cell therapy, CLBS16, in coronary microvascular dysfunction (CMD), is an important development milestone. While concerns regarding the therapy’s scalability, potential cost and durability of the treatment effect will impact its market uptake, the drug is forecast to generate US sales of $364m by 2028, according to GlobalData, a leading data and analytics company. Kelly Lambrinos, Managing Analyst at GlobalData, comments: “There are no drugs that specifically […]
Read more

Verana Health will strengthen Janssen’s presence in ophthalmology in long-term, says GlobalData

Janssen Pharmaceuticals has recently partnered with Verana Health, which is specialized in data analytics in the field of ophthalmology and urology. The collaboration can help Janssen to derive clinical and business insights that can be critical for the development of drugs and understanding current treatment paradigms in ophthalmology in the long-term, says GlobalData, a leading […]
Read more

Tidepool Loop app will be game-changing for type 1 diabetes management

If Tidepool’s diabetes management app Tidepool Loop gains its 510(k) clearance from the Food and Drug Administration (FDA), it will have a significant impact on patients’ ability to attain glycemic control, says GlobalData, a leading data and analytics company. This is especially prominent as only 20-30% of type 1 diabetes (T1D) patients meet their glycemic […]
Read more

Keytruda set to overthrow Adcetris monotherapy in the transplant ineligible setting in Hodgkin’s lymphoma following EU and FDA nod, says GlobalData

The FDA and EMA’s recent positive opinions on the expanded use of Merck & Co’s Keytruda (pembrolizumab) has the drug all set to catch up to Seagen’s Adcetris (brentuximab vedotin) in the transplant ineligible setting, according to GlobalData, a leading data and analytics company. The expansion is also likely to have a significant impact on […]
Read more

New COVID-19 strains are causing clinical trial resumptions to slow

Many clinical trials were set to resume activity as the initial peak of the COVID-19 virus started declining. However, with the number of confirmed COVID-19 cases rising globally, especially in Western areas such as the US and Europe, along with two more infectious variants of COVID-19, this has led to increased restrictive measures and has […]
Read more
1 … 68 69 70 71 72 … 108